[Skip to Content]
[Skip to Content Landing]
Citations 0
February 9, 2000

Immunologic Strategies for Herpes Vaccination—Reply

Author Affiliations

Phil B.FontanarosaMD, Deputy EditorIndividualAuthorStephen J.LurieMD, PhD, Fishbein FellowIndividualAuthor

JAMA. 2000;283(6):746. doi:10.1001/jama.283.6.741

In Reply: Dr Friedman points out the complexities of viral-host interaction with herpesviruses. The gD-gB vaccine did elicit neutralizing antibodies that were enhanced with complement and only antibodies that killed HSV-infected cells in the presence of complement (antibody-dependent cell-mediated cytotoxicity antibodies).1 As Friedman suggests, "paralyzing" immune evasion molecules such as HSV gC, gE, and gI appears to be an attractive strategy for a successful HSV vaccine. It is also clear that the virus directs considerable "offensive energy" toward disarming cellular immune responses.2 The CD8+ T-cell responses to HSV are often directed to internal or tegument proteins.3 Thus, we stand by our comments that greater understanding of cellular and mucosal responses will be helpful in defining immune correlates.

First Page Preview View Large
First page PDF preview
First page PDF preview